Scilex Holding Company — Form 8-K Summary
Business context and reporting period
Scilex Holding Company filed a Current Report on Form 8-K regarding a material financing arrangement entered into on January 8, 2023, with B. Riley Principal Capital II, LLC. The report was signed and filed on January 9, 2023. This filing does not report quarterly or annual operating results.
Financing and key terms
- Scilex received the right, but not the obligation, to sell up to $500 million of common stock to B. Riley over a period extending to the first day of the month following the 36-month anniversary of the effectiveness of the initial registration statement.
- Shares sold under advances would generally be priced at 98% of the Nasdaq volume-weighted average price during the applicable pricing period.
- Each advance is subject to trading-volume limits and is generally capped at 1 million shares, with additional limitations based on the applicable advance type and Nasdaq trading volume.
- B. Riley’s purchases are subject to ownership limits, including a 4.99% voting-power or share-ownership limit and, generally, a 19.9% exchange cap based on shares outstanding at the agreement date. The exchange cap may not apply if the average price of applicable sales is at least $4.87.
- Scilex agreed to pay a $10,000 structuring fee to a B. Riley subsidiary and issue 250,000 common shares as a commitment fee within three trading days after execution.
- B. Riley’s purchase obligation is conditional on, among other matters, SEC effectiveness of a registration statement covering the commitment shares and shares issuable under the facility.
- The commitment shares are being issued in reliance on the Section 4(a)(2) exemption from Securities Act registration, based on B. Riley’s representation that it is an accredited investor.
Financial metrics and liquidity
The filing provides no revenue, profit, cash flow, margin, debt, cash balance, or other operating financial metrics. The facility provides potential access to equity capital, but the filing does not state that any advances had been requested or completed as of the report date.
Material changes versus the prior comparable period
No comparable-period financial information or operating performance is presented. The material change disclosed is the entry into the standby equity purchase agreement and the related commitment-fee issuance.
Outlook, risks, contingencies, and unusual items
- Funding is discretionary for Scilex and is not a committed cash infusion unless the company submits advance notices and all contractual and registration conditions are satisfied.
- Issuances under the facility may substantially dilute existing stockholders, including the immediate issuance of 250,000 commitment shares.
- Shares are sold at a 2% discount to VWAP, and the amount that can be raised depends on market price, trading volume, ownership limits, the exchange cap, and other agreement conditions.
- The company may establish minimum acceptable prices and may discontinue certain advances if market prices fall below specified thresholds.
- The filing does not quantify the expected timing, amount, or use of proceeds from any future advances.
Investor verification points
- Confirm whether the registration statement was filed and declared effective.
- Verify whether any advances or additional advances occurred, including shares issued, gross proceeds, discounts, and net proceeds.
- Review the complete Purchase Agreement filed as Exhibit 10.1 for additional conditions, termination rights, adjustments, and limitations.
- Assess potential dilution from the 250,000 commitment shares and any future equity issuance.
- Reconcile subsequent filings for changes in shares outstanding, ownership limitations, and the company’s actual liquidity needs.